Concern J&J may give Indian hip patients worse deal than US patients
This article was originally published in Scrip
Johnson & Johnson has said it will cover the costs of testing and treating patients in India who had been implanted with the company’s faulty ASR hip devices. However, some experts believe that Indian patients may be getting a raw deal compared with US patients because they are less organized and because most are unaware of the complications the device could have posed. Many may also be unaware of the company's efforts to reach out to them, the experts emphasize.
You may also be interested in...
Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Pfizer Upjohn’s Global President of R&D and Medical, Amrit Ray, discusses in a wide-ranging interview the need for tailored interventions to address the growing burden of non-communicable diseases and efforts around harnessing real world data. He also underscores the importance of investing in primary care and a primary health workforce against the backdrop of outbreaks such as coronavirus.